to HFE include:

• FDA Guidance for Industry: Human Factors Studies and Related Submissions in Medical Device Submissions: This guidance outlines methods for evaluating user interfaces in medical devices to prevent use-related errors.
• FDA Regulations for Combination Products (21 CFR Parts 3, 4): These regulations define the classification and regulatory pathways for combination products.
• General Principles of Software Validation: Relates to the validation of software components of combination products to assess risks adequately.

EMA and MHRA Regulations

The EMA’s regulations also align closely with FDA expectations for HFE. The European Union Medical Device Regulation (EU MDR) requires a thorough assessment of usability while complying with the principles of usability engineering. The MHRA follows similar processes laid out in the UK’s Medical Devices Regulations and EU legislations, ensuring user-centered design approaches are integral for compliance.

Documentation

Proper documentation is critical for demonstrating compliance with HFE principles in combination products. The following elements should be included in the human factors file:

• User Profile and Use Context: Understanding of who will use the product and under what conditions.
• Task Analysis: Detailed examination of tasks users will perform, identifying critical tasks and potential errors.
• Usability Testing Data: Results from formative and summative tests, including usability challenges faced by users during actual use scenarios.
• Risk Management File: Documentation covering the relationship between usability issues and potential patient safety risks.

Usability Engineering Process

The usability engineering process should be structured and documented as follows:

1. Identify Intended Users and Uses: Define the target user population, their characteristics, and how they will interact with the combination product.
2. Conduct User Interface Design: Develop user interfaces with a focus on user-centered design principles, ensuring intuitiveness and minimizing potential use errors.
3. Formative Testing: Perform iterative testing during the development of the product to identify and resolve usability issues before the final product is developed.
4. Summative Testing: Conduct comprehensive usability tests that represent actual use conditions, collecting data on effectiveness and user satisfaction.
5. Final Documentation: Compile all insights and data to create a robust human factors file to submit to relevant regulatory authorities.

Review/Approval Flow

The review and approval process for high-risk combination products incorporating human factors engineering involves several key phases:

1. Pre-submission Consultation: Engage with the FDA early to discuss HFE requirements, potential challenges, and strategies for data collection.
2. Submission of Human Factors File: Include the detailed human factors documentation with either new drug applications (NDA), 510(k) submissions, or PMA applications, depending on the classification of the combination product.
3. FDA Review Process: The FDA will evaluate submitted data against their expectations outlined in relevant guidance documents, focusing on usability testing outcomes, risk mitigations, and user-centered design effectiveness.
4. Post-market Surveillance: Following approval, continuous monitoring of real-world use and performance of the combination product is mandatory. Observing user interactions can help in identifying further optimization opportunities.

Common Deficiencies

When submitting applications involving combination products, certain deficiencies tend to recur. Addressing these proactively can help streamline the review process:

• Inadequate User Needs Definition: Often, submissions lack clarity regarding user profiles and the environments in which the product will be used. A comprehensive user need analysis is vital.
• Poorly Conducted Usability Studies: Tests must be conducted in realistic settings, reflecting actual use conditions. Agencies expect robust, reproducible studies.
• Underestimating Risks Associated with Use Errors: Failure to appropriately address potential misuse of the product can lead to safety issues. Comprehensive risk management practices must be adhered to.
• Insufficient Documentation: Submissions that do not provide comprehensive detail on methods, results, and user feedback may be rejected. Each element of the human factors file should be meticulously documented.

RA-Specific Decision Points

Regulatory Affairs (RA) professionals must make critical decisions at various stages of product development and submission:

• When to File as a Variation vs. New Application: If the changes in design or functionality resulting from HFE testing affect the device’s intended use or safety, it may necessitate a new application submission rather than a variation.
• Justifying Bridging Data: In cases where HFE studies may not directly be applicable across product iterations (e.g., changes in packaging), RA professionals must provide a scientific rationale backed by data on how user expectations and interactions remain consistent.
• Engaging with Regulators Early: Proactively discussing the HFE strategy with regulatory agencies can prevent common pitfalls associated with usability issues and ensure alignment with regulatory expectations. Consultation meetings can offer valuable insights into agency expectations.

Conclusion

Implementing a robust human factors engineering strategy for high-risk combination products is essential for regulatory compliance and product success. RA professionals must navigate FDA expectations carefully, ensuring user needs are met while minimizing risks associated with user interactions. By following a structured process in documentation, engaging early with regulatory agencies, and addressing common deficiencies, organizations can ensure that their combination products are not only compliant but also safe and effective for end-users.